Photo of Christian E Badr,  PhD

Christian E Badr, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 643-3485


badr.christian@mgh.harvard.edu

Christian E Badr, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Neurology, Harvard Medical School
  • Assistant in Neuroscience, Neurology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Glioma, a common form of primary central nervous system tumors, is an aggressive, incurable type of brain tumors. This heterogeneous tumor population, is enriched in a subset of brain-tumor initiating cells or glioma stem cells (GSCs) with self-renewal and tumor initiation capacities. My group is focused on studying the major genetic hubs driving this cancer subpopulation and the molecular aspects governing self-renewal and tumor initiation. In our studies we use a multidisciplinary approach combining targeted small-molecule inhibitors, genetic targeting as well as proteomics to interrogate GSCs and develop novel therapies for brain tumors. Using this approach, we have identified metabolic dependencies in highly aggressive GSCs which can be exploited to specifically target these cells. We are also interested in studying tumor plasticity, in particular the ability of GSCs to change their transcriptional profile in response to different environmental or therapeutic insults, thereby favoring a more aggressive and resistant tumor population.

Publications

Powered by Harvard Catalyst
  • Crommentuijn MH, Kantar R, Noske DP, Vandertop WP, Badr CE, Würdinger T, Maguire CA, Tannous BA. Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. Mol Ther Oncolytics 2016; 3:16017. PubMed
  • Crommentuijn MH, Maguire CA, Niers JM, Vandertop WP, Badr CE, Würdinger T, Tannous BA. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Mol Oncol 2015. PubMed
  • Lai CP, Kim EY, Badr CE, Weissleder R, Mempel TR, Tannous BA, Breakefield XO. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun 2015; 6:7029. PubMed
  • Teng J, Hejazi S, Badr CE, Tannous BA. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells 2014. PubMed
  • Badr CE. Bioluminescence imaging: basics and practical limitations. Methods Mol Biol 2013; 1098:1-18. PubMed
  • Amante RJ, Badr CE. Cell-based bioluminescence screening assays. Methods Mol Biol 2013; 1098:185-95. PubMed
  • Badr CE, Van Hoppe S, Dumbuya H, Tjon-Kon-Fat LA, Tannous BA. Targeting cancer cells with the natural compound obtusaquinone. Journal of the National Cancer Institute 2013. PubMed
  • Maguire CA, Bovenberg MS, Crommentuijn MH, Niers JM, Kerami M, Teng J, Sena-Esteves M, Badr CE, Tannous BA. Triple bioluminescence imaging for in vivo monitoring of cellular processes. Mol Ther Nucleic Acids 2013; 2:e99. PubMed
  • Badr CE, Tannous BA. Bioluminescence imaging: progress and applications. Trends Biotechnol 2011. PubMed
  • Badr CE, Wurdinger T, Nilsson J, Niers JM, Whalen M, Degterev A, Tannous BA. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. 2011. PubMed
  • Badr CE, Wurdinger T, Tannous BA. Functional Drug Screening Assay Reveals Potential Glioma Therapeutics. 2010. PubMed
  • Badr CE, Hewett JW, Breakefield XO, Tannous BA. A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS ONE 2007; 2:e571. PubMed
  • Badr CE, Niers JM, Tjon-Kon-Fat LA, Noske DP, Wurdinger T, Tannous BA. Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models. Mol Imaging 2009; 8:278-90. PubMed
Hide